DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
15006546
DOI
10.1016/j.bcp.2003.11.001
PII: S0006295203008839
Knihovny.cz E-resources
- MeSH
- DNA Adducts metabolism MeSH
- Cell Division drug effects MeSH
- Cell Extracts MeSH
- Circular Dichroism MeSH
- Cisplatin pharmacology MeSH
- DNA drug effects metabolism MeSH
- Transcription, Genetic drug effects MeSH
- HeLa Cells MeSH
- Humans MeSH
- Organoplatinum Compounds pharmacology MeSH
- HMGB1 Protein metabolism MeSH
- Antineoplastic Agents pharmacology MeSH
- Cross-Linking Reagents MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- DNA Adducts MeSH
- Cell Extracts MeSH
- Cisplatin MeSH
- DNA MeSH
- Organoplatinum Compounds MeSH
- HMGB1 Protein MeSH
- Antineoplastic Agents MeSH
- Cross-Linking Reagents MeSH
- transplatin MeSH Browser
The global modification of mammalian and plasmid DNAs by novel platinum compounds, trans-[PtCl(2)(NH(3))(Am)], where Am=2 -methylbutylamine or sec-butylamine was investigated in cell-free media using various biochemical and biophysical methods. These modifications were analyzed in the context of the activity of these new compounds in several tumor cell lines including those resistant to antitumor cis-diamminedichloroplatinum(II) (cisplatin). The results showed that the replacement of one amine group by 2-methylbutylamine or sec-butylamine ligand in clinically ineffective trans-diamminedichloroplatinum(II) (transplatin) resulted in a radical enhancement of its activity in tumor cell lines so that they are more cytotoxic than cisplatin and exhibited significant antitumor activity including activity in cisplatin-resistant tumor cells. Importantly, this replacement also markedly altered DNA binding mode of transplatin and reduced the efficiency of repair systems to remove the adducts of the new analogues from DNA. The results support the view that one strategy to activate trans geometry in bifunctional platinum(II) compounds including circumvention of resistance to cisplatin may consist in a chemical modification of the ineffective transplatin which results in an increased efficiency to form DNA interstrand cross-links.
References provided by Crossref.org
Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding